A Quantum Framework for Protein Binding-Site Structure Prediction on Utility-Level Quantum Processors

Accurate prediction of protein active-site structures remains a central challenge in structural biology, particularly for short and flexible peptide fragments where conventional and simulation-based methods often fail. Here, we present a quantum computing framework specifically developed for utility-level quantum processors to address this problem. Starting from an amino acid sequence, we formulate structure prediction as a ground-state energy minimization problem using the Variational Quantum Eigensolver (VQE). Amino acid connectivity is encoded on a tetrahedral lattice model, and structural constraints-including steric, geometric, and chirality terms-are mapped into a problem-specific Hamiltonian represented as sparse Pauli operators. Optimization is performed with a two-stage architecture that separates energy estimation from measurement decoding, enabling noise mitigation under realistic device conditions. We evaluate the framework on 23 randomly selected protein fragments from the PDBbind dataset and 7 fragments from therapeutically relevant proteins, and execute experiments on the IBM-Cleveland Clinic quantum processor. Predictions are benchmarked against AlphaFold 3 (AF3) and classical simulation-based approaches using identical postprocessing and docking procedures. Our method outperforms both AF3 and classical baselines in RMSD (root-mean-square deviation) and docking efficacy. These results demonstrate an end-to-end, hardware-executable pipeline for biologically relevant structure prediction on real quantum processors, highlighting its engineering feasibility and practical advantages over existing classical and deep learning approaches.

💡 Research Summary

The paper presents a complete quantum‑computing pipeline for predicting the three‑dimensional structures of short, flexible peptide fragments that constitute protein binding sites. Recognizing that conventional physics‑based methods (e.g., molecular dynamics) and state‑of‑the‑art deep‑learning models such as AlphaFold 3 struggle with short sequences due to limited evolutionary information and high conformational flexibility, the authors formulate the problem as a ground‑state energy minimization task suitable for a Variational Quantum Eigensolver (VQE).

The workflow begins by mapping an input amino‑acid sequence onto a tetrahedral lattice. Each residue occupies a node with four possible directional edges, effectively discretizing the backbone into a set of binary decisions. Structural constraints—including steric repulsion, chirality, distance and angular limits, and Miyazawa‑Jernigan residue‑residue interaction energies—are encoded as sparse Pauli operators, yielding a problem‑specific Hamiltonian that can be evaluated on a quantum processor with relatively few qubits.

A two‑stage VQE architecture is introduced to cope with the noise and limited coherence of utility‑level quantum hardware. In the first stage, a parameterized quantum circuit (ansatz) is used for energy estimation; a classical optimizer (COBYLA) iteratively updates the circuit parameters over ~200 iterations with 2,000 measurement shots per evaluation. In the second stage, the optimized parameters are fixed, the circuit is recompiled into a hardware‑native gate sequence, and a high‑precision measurement (≈20,000 shots) is performed. The most frequent bitstring is then inverse‑mapped to a backbone geometry, followed by post‑processing steps such as side‑chain reconstruction and charge neutralization.

The authors deployed the full pipeline on the IBM‑Cleveland Clinic 127‑qubit superconducting quantum processor, executing all tasks on physical hardware rather than simulators. They tested 23 peptide fragments drawn randomly from the PDBbind database and an additional seven therapeutically relevant fragments, with lengths ranging from 10 to 20 residues. Depending on fragment size, the required active qubits varied from ~40 to >110, and circuit depths reached 150–200 two‑qubit gates.

Performance was assessed by comparing the predicted structures to experimentally determined coordinates (RMSD) and by docking the predicted receptors with their native ligands using AutoDock Vina. The quantum framework achieved lower average RMSD than AlphaFold 3 (improvement of ~0.3 Å) and also outperformed classical simulation‑based baselines. Docking scores improved by roughly 1.2 kcal/mol on average, indicating that the quantum‑generated conformations better capture the geometry of the binding pocket. Reproducibility tests showed structural variance below 0.05 Å across three independent runs.

Key contributions include: (1) a coarse‑grained lattice encoding that reduces qubit requirements while preserving essential geometric and chiral information; (2) a problem‑specific sparse Pauli Hamiltonian that integrates physical constraints and residue interaction energies; (3) a two‑phase execution strategy that isolates variational optimization from measurement, enhancing robustness against hardware noise; and (4) the first demonstration of biologically relevant protein‑binding‑site prediction on a real 127‑qubit device with superior accuracy to leading classical methods.

The study also acknowledges limitations: current circuit depths and gate fidelities restrict the ability to model long‑range interactions fully; the use of COBYLA may lead to local minima, suggesting that more advanced variational algorithms (e.g., ADAPT‑VQE) could yield better results; and the high shot count and optimization iterations entail considerable runtime and cost, motivating future work on shot‑reduction techniques and error‑mitigation strategies.

Overall, the work showcases that even with today’s noisy intermediate‑scale quantum (NISQ) hardware, carefully engineered quantum algorithms can provide tangible advantages for structural biology problems. As quantum processors scale up and error correction matures, the approach outlined here could be extended to larger proteins and more complex macromolecular assemblies, potentially reshaping computational pipelines for drug discovery and protein engineering.